Next generation of Trojan-horse drugs designed to minimize damage to healthy cells
Problems with current antibody agents:
"But this approach has proved tricky to realize. Sometimes the molecular linkers are too tight, and do not release the drug inside the cell. Sometimes they are too unstable, and release the drug near healthy cells—limiting the dose that can be administered. Even the drugs themselves can be problematic: because most are toxic mainly to rapidly dividing cells, they can leave behind the slowly dividing cells that seed some tumours. And some have had trouble penetrating more than a few cell layers into their target tumours."